Search
Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.
A new imaging approach being investigated by Memorial Sloan Kettering researchers could provide better information about a tumor’s molecular activity, allowing for a more accurate diagnosis.
A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.
Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.
Cell biologist Michael Overholtzer will succeed DNA replication expert Ken Marians.
Seven students have successfully defended their dissertations and will receive their PhD degrees at commencement on May 18.
Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.
Developed by scientists at MSK and the University of British Columbia/BC Cancer, the platform provides the deepest look yet into tumor evolution.
Scott N. Keeney, a member of the Molecular Biology Program within the Sloan Kettering Institute, was one of 56 researchers to be appointed a Howard Hughes Medical Institute (HHMI) investigator in 2008.